BioLineRx (NASDAQ:BLRX) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report issued on Saturday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reduced their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a report on Monday, November 25th.

BioLineRx Stock Up 0.2 %

Shares of BLRX stock opened at $0.14 on Friday. The firm has a fifty day moving average of $0.30 and a 200-day moving average of $0.51. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. BioLineRx has a 12-month low of $0.14 and a 12-month high of $1.52. The company has a market capitalization of $11.42 million, a price-to-earnings ratio of -0.65 and a beta of 1.46.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. PVG Asset Management Corp acquired a new stake in BioLineRx in the second quarter valued at $70,000. CVI Holdings LLC acquired a new stake in BioLineRx in the second quarter valued at $462,000. Finally, Atria Investments Inc lifted its stake in BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 29,193 shares during the last quarter. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.